Markus Schwaiger

Active 1984–2025

368
Papers
67,660
Citations
152
h-index
353
i10-index

Citations

Citations per year for Markus Schwaiger1972: 1 citations1980: 1 citations1983: 1 citations1984: 3 citations1985: 1 citations1986: 6 citations1987: 9 citations1988: 30 citations1989: 50 citations1990: 46 citations1991: 51 citations1992: 74 citations1993: 86 citations1994: 82 citations1995: 79 citations1996: 90 citations1997: 110 citations1998: 141 citations1999: 166 citations2000: 163 citations2001: 260 citations2002: 296 citations2003: 383 citations2004: 452 citations2005: 615 citations2006: 569 citations2007: 641 citations2008: 637 citations2009: 682 citations2010: 559 citations2011: 631 citations2012: 578 citations2013: 522 citations2014: 564 citations2015: 461 citations2016: 565 citations2017: 600 citations2018: 511 citations2019: 1,660 citations2020: 1,505 citations2021: 1,439 citations2022: 1,052 citations2023: 672 citations2024: 1,036 citations2025: 435 citations2026: 14 citations1973–1979: no citations, so these years are not shown1981–1982: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,989 citing papers, 25.3% of this breakdownGermany: 2,681 citing papers, 13.6% of this breakdownUnited Kingdom: 1,258 citing papers, 6.4% of this breakdownChina: 1,229 citing papers, 6.2% of this breakdownItaly: 998 citing papers, 5.1% of this breakdownNetherlands: 851 citing papers, 4.3% of this breakdownFrance: 699 citing papers, 3.6% of this breakdownCanada: 682 citing papers, 3.5% of this breakdownSwitzerland: 646 citing papers, 3.3% of this breakdownJapan: 577 citing papers, 2.9% of this breakdownAustralia: 509 citing papers, 2.6% of this breakdownBelgium: 412 citing papers, 2.1% of this breakdown
0%25.3%Other 21.1%

Fields

  • Medicine73.5%
  • Biochemistry, Genetics and Molecular Biology7.3%
  • Neuroscience6.4%
  • Immunology and Microbiology4.1%
  • Engineering2%
  • Computer Science1.7%
  • Other5%

Topics

  • Medical Imaging Techniques and Applications6.3%
  • Radiopharmaceutical Chemistry and Applications4.4%
  • Prostate Cancer Treatment and Research4%
  • Cardiac Imaging and Diagnostics3.3%
  • Prostate Cancer Diagnosis and Treatment2.6%
  • Advanced MRI Techniques and Applications2.3%
  • Other77.1%

Coauthors

All papers

Open in search
  1. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernd Engelmann, Steffen Maßberg - The Journal of Experimental Medicine 2012 cited by 1,800

  2. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 301

  3. Radiotheranostics: a roadmap for future development

    Authors: , , , , , , , , - The Lancet Oncology 2020 cited by 303

  4. Current use of PSMA–PET in prostate cancer management

    Authors: , , , - Nature Reviews Urology 2016 cited by 622

  5. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

    Authors: , , , , , , , , , , , - Journal of Nuclear Medicine 2015 cited by 532

  6. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

    Authors: , , , , , , , , , , , , - European Urology 2018 cited by 308

  7. Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer

    Authors: , , , , , , , , , , , - The Journal of Urology 2015 cited by 783

  8. Exploring the Role of RGD-Recognizing Integrins in Cancer

    Authors: , , , , , , , , , - Cancers 2017 cited by 440

  9. Radiation Dosimetry for177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions

    Authors: , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2016 cited by 216

  10. Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy

    Authors: , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2018 cited by 332

  11. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

    Authors: , , , , , , , , , , , , - Journal of Nuclear Medicine 2015 cited by 995

  12. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer

    Authors: , , , , , , , , , , - European Urology 2016 cited by 577

  13. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors

    Authors: , , , , , , - Journal of Nuclear Medicine 2019 cited by 148

  14. Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner

    Authors: , , , , , , , - Journal of Nuclear Medicine 2011 cited by 876

  15. Preclinical Evaluation and First Patient Application of99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer

    Authors: , , , , , , - Journal of Nuclear Medicine 2016 cited by 228

  16. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , S. Eschmann, W. Dornoff, Birgit Siekmeyer, L Trampert, G. Gademann, Thomas Brunner, A Amthauer, Jens Ricke, Maciej Pech, Christian Rübe, Claudia Kirsch, S. Ezzidin, Heinz Schmidberger, M. Schreckenberger, M. Bamberg, Daniel Zips, Roland Bares, Christian la Fougère, Volker Budach, Winfried Brenner, Marcus Beck, R Freiherr von Gumppenberg, Daniel M. Aebersold, T Krause, H J Feldmann, A. Hertel, Georg Stüben, J. Sciuk, H Annweiler, G. Höll, W Oehler, I Schlöcker, R. Baum, B. Kimmig, Jürgen Dunst, E Henze, Ulf Lützen, Markus Schwaiger, Katharina Strehle, Winfried Alberti, Marc D. Piroth, Marco Tosch, Richard Pötter, Joachim Widder, Christian Herold, U Freund, Felix Momm, Wolfgang Weber, Marie‐Luise Sautter‐Bihl, Klaus Tatsch, Guido Hildebrandt, Bernd‐Joachim Krause - The Lancet Oncology 2020 cited by 177

  17. Anatomic Versus Physiologic Assessment of Coronary Artery Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2013 cited by 564

  18. 99mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer

    Authors: , , , , , , , , , , , , , - European Urology 2018 cited by 246

  19. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors

    Authors: , , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2017 cited by 195

  20. Emerging molecular imaging targets and tools for myocardial fibrosis detection

    Authors: , , , , , , , , , - European Heart Journal - Cardiovascular Imaging 2022 cited by 60

  21. Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning

    Authors: , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2022 cited by 53

  22. Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations

    Authors: , , , , , , , , , - Journal of Clinical Oncology 2000 cited by 554

  23. TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis

    Authors: , , , , , , , , , , , , , , , , - Cancer Cell 2008 cited by 301

  24. PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent

    Authors: , , , , , , , , , - Journal of Nuclear Medicine 2011 cited by 222